비교리스트

 카트 문의
시장보고서
상품코드
1662078

세계의 바이오의약품 시장

Biopharmaceuticals
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 262 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 바이오의약품 시장, 2030년에는 8,829억 달러에 도달할 전망

2024년에 4,438억 달러로 추정되는 바이오의약품 세계 시장은 2024-2030년간 CAGR 12.1%로 성장하여 2030년에는 8,829억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 단일클론항체는 CAGR 10.0%를 나타내고, 분석 기간 종료시에는 2,882억 달러에 이를 것으로 예상됩니다. 에리스로포이에틴 부문의 성장률은 분석 기간중 CAGR 13.2%를 나타낼 전망입니다.

미국 시장은 1,199억 달러로 추정, 중국은 CAGR 16.1%로 성장 예측

미국의 바이오의약품 시장은 2024년에 1,199억 달러에 이른 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 1,886억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년간 CAGR은 16.1%를 나타낼 전망입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 9.2%와 10.3%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 9.5%로 성장할 것으로 예측됩니다.

세계의 바이오의약품 시장 동향과 촉진요인 정리

생명공학과 의약품 제조의 역동적인 교집합인 바이오의약품은 암, 당뇨병, 심혈관 질환, 면역 질환 등 심각한 건강 상태에 대한 표적 치료제를 제공함으로써 현대 의학에 혁명을 일으키고 있습니다. 이들 의약품은 단백질, 당류, DNA, RNA와 같은 핵산 또는 이들의 조합으로 구성되며, 인간, 동물, 식물, 곰팡이, 미생물 등의 생물체에서 유래합니다. 바이오의약품의 특징은 체내에 자연적으로 존재하는 화합물과 구조적으로 유사하여 그 효능과 생물학적 과정으로의 통합성을 높인다는 점입니다. 이러한 유사성을 통해 질병 세포를 보다 정확하게 표적화할 수 있어 치료 효과의 향상과 부작용의 감소로 이어집니다. 바이오 의약품 생산에는 재조합 단백질 생산, 줄기세포 및 혈액 성분의 이용 등 고도의 유전자 기술이 관여하고 있으며, 이 분야의 다용도성과 가능성을 보여주고 있습니다.

바이오의약품 산업은 기존 의약품이 가지고 있지 않은 몇 가지 장점을 가지고 있습니다. 바이오 의약품은 복잡한 질병이나 희귀질환을 앓고 있는 환자의 삶의 질을 개선하고 수명을 연장하여 전체 의료 비용을 절감할 수 있습니다. 바이오 의약품의 표적화된 접근 방식은 여러 신체 시스템에 영향을 미치는 기존 의약품에 비해 일반적으로 부작용이 적습니다. 바이오 의약품의 부상은 의약품 개발 과정을 통해 더 깊은 통찰력을 제공하는 기술 발전으로 인해 개인화된 의료에 대한 수요가 증가하고 있는 것과 일치합니다. 기업들은 데이터 기반 접근 방식을 채택하고 머신러닝과 인공지능을 활용하여 방대한 데이터 세트를 분석하여 약물과 질병의 상호 작용을 더 깊이 이해하고 연구 개발 전략을 최적화하고 있습니다. 이러한 정밀의료로의 전환은 보다 효과적이고 맞춤화된 치료법을 창출하는 원동력이 되고 있으며, 바이오 의약품을 의료 혁신의 최전선에 위치시키고 있습니다.

바이오의약품 시장의 성장은 몇 가지 중요한 요인에 의해 주도되고 있는데, GastroPlus(R) 및 ADMET Predictor와 같은 고급 시뮬레이션 소프트웨어와 정밀 모델링 도구는 인간의 약동학을 예측하고 후기 단계에서의 실패를 최소화함으로써 의약품 개발의 초기 단계를 강화합니다. 하이스루풋 스크리닝 기술은 수많은 약물 후보물질의 신속한 평가를 가능하게 하고, 선택 과정을 간소화합니다. 나노기술은 난용성 및 난투과성 약물의 생체 이용률을 향상시키고 사용 가능한 화합물의 범위를 확대하는 데 중요한 역할을 하고 있습니다. 환자 중심의 의약품 개발 추세는 개인 맞춤형 의료를 지원하고, 특정 환자 하위 그룹에 대한 치료 동향을 최적화하며, 컴플라이언스를 개선하는 데 도움이 됩니다. Classification System(DCS)과 같은 규제 지원은 승인을 간소화하고 특정 임상시험을 면제함으로써 개발 비용을 절감합니다. 스마트 약물 전달 시스템과 같은 디지털 헬스 기술의 통합은 실시간 모니터링과 동적 투약 조정을 가능하게 하여 환자 관리를 강화할 수 있습니다. 또한, 환경적 지속가능성이 점점 더 중요해지고 있는 가운데, 생물약학은 폐기물을 줄이고 효율성을 향상시키기 위해 제제를 최적화함으로써 환경 친화적인 제약 관행에 기여하고 있습니다.

바이오의약품이 지속적으로 발전함에 따라 보다 개인화되고 효과적인 헬스케어 솔루션을 제공하여 전 세계적으로 치료 패러다임을 변화시킬 것으로 기대되고 있습니다. 개별 유전자 프로파일에 맞춘 표적치료제에 대한 업계의 관심은 현재 관리하기 어려운 질병을 보다 쉽게 통제하고 치료할 수 있는 미래를 예감케 합니다. 바이오의약품 기술의 지속적인 발전과 개인 맞춤형 의료에 대한 관심이 높아짐에 따라 이 분야의 성장과 영향력이 크게 증가하여 전 세계 수십억 명의 사람들에게 혜택을 줄 수 있게 될 것입니다. 이러한 지속적인 발전은 헬스케어의 발전, 기술 혁신의 촉진, 다양한 질환의 환자 결과 개선에 있어 바이오의약품의 중요성을 강조하고 있습니다.

부문

유형(단일클론항체, 에리스로포이에틴, 인슐린, 백신, 인터페론, 성장인자 및 응고인자, 호르몬, 기타 유형), 용도(종양학, 혈액 질환, 심혈관 질환, 대사성 질환, 감염 질환, 면역학, 신경 질환, 기타 용도)

조사 대상 기업 예(214개사)

  • Abbott Diagnostics, Inc.-Core Laboratory
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Sanofi

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.03.11

Global Biopharmaceuticals Market to Reach US$882.9 Billion by 2030

The global market for Biopharmaceuticals estimated at US$443.8 Billion in the year 2024, is expected to reach US$882.9 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2024-2030. Monoclonal Antibody, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$288.2 Billion by the end of the analysis period. Growth in the Erythropoietin segment is estimated at 13.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$119.9 Billion While China is Forecast to Grow at 16.1% CAGR

The Biopharmaceuticals market in the U.S. is estimated at US$119.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$188.6 Billion by the year 2030 trailing a CAGR of 16.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.

Global Biopharmaceuticals Market - Key Trends and Drivers Summarized

Biopharmaceuticals, a dynamic intersection of biotechnology and pharmaceutical manufacturing, are revolutionizing modern medicine by offering targeted treatments for severe health conditions such as cancer, diabetes, cardiovascular diseases, and immune disorders. These drugs, composed of proteins, sugars, nucleic acids like DNA and RNA, or a combination thereof, are derived from living organisms, including humans, animals, plants, fungi, and microbes. What distinguishes biopharmaceuticals is their structural similarity to naturally occurring compounds in the body, which enhances their effectiveness and integration into biological processes. This alignment allows for more precise targeting of diseased cells, resulting in improved therapeutic outcomes and reduced side effects. Biopharmaceutical production involves advanced genetic techniques, including the creation of recombinant proteins and the use of stem cells and blood components, showcasing the field's versatility and potential.

The biopharmaceutical industry offers several advantages over traditional pharmaceuticals. Biopharmaceuticals can lower overall healthcare costs by improving the quality of life and extending life expectancy for patients with complex diseases and rare disorders. Their targeted approach typically results in fewer side effects compared to conventional drugs, which often affect multiple body systems. The rise of biopharmaceuticals aligns with the increasing demand for personalized medicine, enabled by technological advancements that provide deeper insights throughout the drug development process. Companies are adopting data-driven approaches, leveraging machine learning and artificial intelligence to analyze vast datasets, better understand drug-disease interactions, and optimize research and development strategies. This shift towards precision medicine is driving the creation of more effective, tailored treatments and positioning biopharmaceuticals at the forefront of medical innovation.

The biopharmaceutical market's growth is driven by several key factors. Advanced simulation software and precision modeling tools like GastroPlus® and ADMET Predictor enhance early drug development by predicting human pharmacokinetics and minimizing late-stage failures. High-throughput screening technologies facilitate the rapid assessment of numerous drug candidates, streamlining the selection process. Nanotechnology plays a crucial role in enhancing the bioavailability of poorly soluble and permeable drugs, expanding the range of viable compounds. The trend towards patient-centric drug development supports personalized medicine, optimizing treatments for specific patient subgroups and improving compliance. Regulatory support, such as the Biopharmaceutics Classification System (BCS) and the Developability Classification System (DCS), streamlines approvals and reduces development costs by waiving certain clinical studies. The integration of digital health technologies, such as smart drug delivery systems, allows for real-time monitoring and dynamic dosing adjustments, enhancing patient management. Additionally, environmental sustainability is becoming increasingly important, with biopharmaceutics contributing to greener pharmaceutical practices by optimizing formulations to reduce waste and improve efficiency.

As biopharmaceuticals continue to evolve, they promise to transform treatment paradigms globally, offering more personalized, effective healthcare solutions. The industry's focus on targeted therapies tailored to individual genetic profiles heralds a future where diseases that are currently difficult to manage become more controllable and treatable. The continuous advancement in biopharmaceutical technology, coupled with a growing emphasis on personalized medicine, positions the sector for significant growth and impact, benefiting billions of people worldwide. This ongoing evolution underscores the importance of biopharmaceuticals in advancing healthcare, driving innovation, and improving patient outcomes across a wide range of medical conditions.

SCOPE OF STUDY:

The report analyzes the Biopharmaceuticals market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone, Other Types); Application (Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 214 Featured) -

  • Abbott Diagnostics, Inc. - Core Laboratory
  • Amgen, Inc.
  • Biogen, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Sanofi

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biopharmaceuticals - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Chronic Diseases Drives Growth in Biopharmaceuticals Market
    • Advances in Biotechnology Propel Market Expansion
    • Growing Focus on Personalized Medicine Expands Addressable Market Opportunities
    • Rising Adoption of Biologic Drugs Strengthens Business Case for Biopharmaceuticals
    • Integration with Advanced Drug Delivery Systems Generates Demand for Biopharmaceuticals
    • Technological Innovations in Genetic Engineering Propel Market Growth
    • Increasing Use of Biopharmaceuticals in Oncology Spurs Market Expansion
    • Advances in Monoclonal Antibodies Enhance Demand for Biopharmaceuticals
    • Growing Focus on Biosimilars Expands Market Opportunities
    • Rising Demand for Targeted Therapies Drives Adoption of Biopharmaceuticals
    • Advances in Cell and Gene Therapies Propel Growth in Biopharmaceuticals Market
    • Increasing Regulatory Approvals for Biopharmaceuticals Generate Market Demand
    • Technological Innovations in Bioprocessing Propel Market Expansion
    • Growing Use of Biopharmaceuticals in Rare Diseases Spurs Market Growth
    • Rising Investment in Research and Development Expands Addressable Market for Biopharmaceuticals
    • Focus on Reducing Healthcare Costs Drives Adoption of Biopharmaceutical Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Monoclonal Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Monoclonal Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Interferon by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Interferon by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Interferon by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Growth & Coagulation Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Growth & Coagulation Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Growth & Coagulation Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Blood Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Blood Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Blood Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Metabolic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Metabolic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Metabolic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 42: World 15-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 45: World 15-Year Perspective for Neurological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 46: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 48: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 49: World Biopharmaceuticals Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Biopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 116: Russia Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Russia Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Russia 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Biopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 137: Australia Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Australia Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Australia 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Australia Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Australia Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Australia 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 143: India Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: India Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: India 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: India Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: India Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: India 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 149: South Korea Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: South Korea Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: South Korea 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: South Korea Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: South Korea Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: South Korea 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 155: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Asia-Pacific Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Asia-Pacific 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Asia-Pacific Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Asia-Pacific 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 161: Latin America Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Latin America Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Latin America 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Latin America Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Latin America Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Latin America 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 167: Latin America Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Latin America Historic Review for Biopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Latin America 15-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 170: Argentina Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Argentina Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Argentina 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Argentina Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Argentina Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Argentina 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 176: Brazil Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Brazil Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Brazil 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Brazil Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Brazil Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Brazil 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 182: Mexico Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Mexico Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Mexico 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Mexico Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Mexico Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Mexico 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 188: Rest of Latin America Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Latin America Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Latin America 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Latin America Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Latin America Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Latin America 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 194: Middle East Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Middle East Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Middle East 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: Middle East Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Middle East Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Middle East 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 200: Middle East Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Middle East Historic Review for Biopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Middle East 15-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 203: Iran Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Iran Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Iran 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: Iran Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Iran Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Iran 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 209: Israel Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Israel Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Israel 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 212: Israel Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Israel Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Israel 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 215: Saudi Arabia Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Saudi Arabia Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Saudi Arabia 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 218: Saudi Arabia Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Saudi Arabia Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Saudi Arabia 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 221: UAE Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: UAE Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: UAE 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 224: UAE Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: UAE Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: UAE 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 227: Rest of Middle East Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Middle East Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Middle East 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Middle East Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Middle East Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Middle East 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Biopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 233: Africa Recent Past, Current & Future Analysis for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Africa Historic Review for Biopharmaceuticals by Type - Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Africa 15-Year Perspective for Biopharmaceuticals by Type - Percentage Breakdown of Value Sales for Monoclonal Antibody, Erythropoietin, Insulin, Vaccine, Interferon, Growth & Coagulation Factor, Hormone and Other Types for the Years 2015, 2025 & 2030
    • TABLE 236: Africa Recent Past, Current & Future Analysis for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Africa Historic Review for Biopharmaceuticals by Application - Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Africa 15-Year Perspective for Biopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Blood Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology, Neurological Disease and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제